• English
    • Ελληνικά
  • English 
    • English
    • Ελληνικά
  • Login
Browsing by Subject 
  •   Home
  • Browsing by Subject
  •   Home
  • Browsing by Subject
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browsing by Subject "Drug dose reduction"

  • 0-9
  • Α
  • Β
  • Γ
  • Δ
  • Ε
  • Ζ
  • Η
  • Θ
  • Ι
  • Κ
  • Λ
  • Μ
  • Ν
  • Ξ
  • Ο
  • Π
  • Ρ
  • Σ
  • Τ
  • Υ
  • Φ
  • Χ
  • Ψ
  • Ω
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sort by:

Order:

Results:

Now showing items 1-7 of 7

  • title
  • submit date
  • accessioned date
  • ascending
  • descending
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
    • Article  

      CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group 

      Economopoulos, T.; Psyrri, A.; Dimopoulos, M. A.; Kalogera-Fountzila, Anna; Pavlidis, Nicholas; Tsatalas, C.; Nikolaides, C.; Mellou, S.; Xiros, N.; Fountzilas, George (2007)
      Background: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) ...

    • Article  

      The diagnosis and management of gastric cancer: Expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010 

      Cutsem, E. van; Dicato, M.; Geva, R.; Arber, N.; Bang, Y.; Benson, A.; Cervantes, A.; Diaz-Rubio, E.; Ducreux, M.; Glynne-Jones, R.; Grothey, Axel; Haller, D.; Haustermans, K.; Kerr, D.; Nordlinger, B.; Marshall, J.; Minsky, B. D.; Kang, Y. K.; Labianca, R.; Lordick, F.; Ohtsu, A.; Pavlidis, Nicholas; Roth, A.; Rougier, P.; Schmoll, H. J.; Sobrero, A.; Tabernero, Josep; Velde, C. van de; Zalcberg, J. (2011)
      Well-recognized experts in the field of gastric cancer discussed during the 12th European Society Medical Oncology (ESMO)/World Congress Gastrointestinal Cancer (WCGIC) in Barcelona many important and controversial topics ...

    • Article  

      Docetaxel-induced enterocolitis: A serious and potentially fatal adverse event 

      Boussios, Stergios; Pentheroudakis, George; Kamina, S.; Katsanos, K.; Pavlidis, Nicholas (2011)

    • Article  

      Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors 

      Pentheroudakis, George; Fountzilas, George; Kalofonos, H. P.; Golfinopoulos, Vassilis; Aravantinos, Gerasimos; Bafaloukos, Dimitrios; Papakostas, P.; Pectasides, Dimitrios; Christodoulou, C.; Syrigos, K.; Economopoulos, T.; Pavlidis, Nicholas (2008)
      Introduction: Cancer in the elderly is a common health issue in developed societies. We sought to present epidemiology, management and outcome data on fit elderly patients with common metastatic cancers and to identify ...

    • Article  

      Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: A study by the EORTC-PAMM-NDDG 

      Joerger, M.; Huitema, A. D. R.; Richel, D. J.; Dittrich, C.; Pavlidis, Nicholas; Briassoulis, E. Ch; Vermorken, J. B.; Strocchi, E.; Martoni, A.; Sorio, R.; Sleeboom, H. P.; Izquierdo, M. A.; Jodrell, D. I.; Féty, R.; Bruijn, E. De; Hempel, G.; Karlsson, M.; Tranchand, B.; Schrijvers, A. H. G. J.; Twelves, C.; Beijnen, J. H.; Schellens, J. H. M. (2007)
      Aims: To investigate the population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients. Patients and methods: Sixty-five female patients with early or advanced breast cancer ...

    • Article  

      Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: A study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group 

      Joerger, M.; Huitema, A. D. R.; Richel, D. J.; Dittrich, C.; Pavlidis, Nicholas; Briassoulis, E. Ch; Vermorken, J. B.; Strocchi, E.; Martoni, A.; Sorio, R.; Sleeboom, H. P.; Izquierdo, M. A.; Jodrell, D. I.; Calvert, H.; Boddy, A. V.; Hollema, H.; Féty, R.; Vijgh, W. J. F. Van Der; Hempel, G.; Chatelut, E.; Karlsson, M.; Wilkins, J.; Tranchand, B.; Schrijvers, A. H. G. J.; Twelves, C.; Beijnen, J. H.; Schellens, J. H. M. (2007)
      Purpose: Paclitaxel and carboplatin are frequently used in advanced ovarian cancer following cytoreductive surgery. Threshold models have been used to predict paclitaxel pharmacokinetic-pharmacodynamics, whereas the time ...

    • Article  

      Systemic treatment-induced gastrointestinal toxicity: Incidence, clinical presentation and management 

      Boussios, Stergios; Pentheroudakis, George; Katsanos, K.; Pavlidis, Nicholas (2012)
      The toxicity of cancer chemotherapy is among the most important factors limiting its use. Clear delineation and communication of benefits and risks is an essential component of treatment decisions. Gastrointestinal toxicity ...

      Browse

      EverywhereCommunities & CollectionsBy Submission DateAuthorsTitlesSubjectsBy TypeBy DepartmentBy Faculty

      My Account

      Login
      Πνευματικά δικαιώματα ©  Βιβλιοθήκη Πανεπιστημίου Κύπρου
      Contact Us | Send Feedback
      Οδηγίες κατάθεσης διδακτορικής διατριβής
      Open Access
      ORCiD